,

,

, tags, etc). The article is 2000+ words and optimized for clarity and search visibility.pgsqlคัดลอกโค้ดPacific Software, Inc. Completes Change of Control with PurMinds Holdings, Takes Leadership in Neuromedicine, Confirms GMP Facility Occupancy and OTCQX Uplisting Strategy

Transformative Corporate Milestone: Pacific Software, Inc. Completes Change of Control with PurMinds Holdings

On January 19, 2026, Pacific Software, Inc. (OTC: PFSF), now operating under the new corporate identity of PurMinds Enterprises, Inc., announced the successful completion of its strategic change of control and Reverse Takeover (RTO) transaction with PurMinds Holdings Inc. This transaction, effective November 3, 2025, marks a major milestone for the Company as it transitions from its former software roots into a clinical-stage precision neuromedicine organization targeting a market valued in excess of $1 trillion globally.

Overview of the Change of Control Transaction

The change of control was executed after Pacific Software entered into a Stock Purchase Agreement with PurMinds Holdings Inc. on August 19, 2025. Under the terms of the agreement, PurMinds Holdings became the majority owner of Pacific Software, resulting in a new corporate vision focused on medical innovation. This transaction effectively aligns the Company with advanced neuromedicine development and research.

The RTO structure allows PurMinds Enterprises to leverage an existing public company shell while quickly scaling operations, research, and development in the neurological health sector. As a clinical-stage organization, PurMinds is dedicated to discovering and developing breakthrough solutions for complex neurological and psychiatric disorders.

Official Corporate Name and Ticker Symbol Transition

In alignment with the new organizational purpose, the Company applied for an official name change to PurMinds Enterprises, Inc. The new name was approved by the State of Nevada and is now in process for exchange listings, including applications to FINRA to update the corporate name and ticker symbol. Although currently still trading as Pacific Software, Inc. on the OTC market under the ticker PFSF, the Company expects its new ticker to reflect the PurMinds identity once the regulatory processes are finalized.

This strategic rebranding places an emphasis on PurMinds’ core mission of advancing early detection and personalized intervention solutions in neurological health — a promising development for investors, clinicians, and patients alike.

Shared Capital and Equity Structure After RTO

Following the close of the RTO, the Company is proceeding with the final issuance of common shares to PurMinds shareholders, pursuant to the agreed 90/10 equity structure laid out in the Share Purchase Agreement. This equity split prioritizes ownership continuity with the PurMinds leadership team, ensuring stability and alignment as the Company progresses on its strategic plan.

In conjunction with these equity issuances, management is actively resolving legacy administrative items carried forward from Pacific Software’s prior operations. These legacy Instructions to the Transfer Agent (ITAI) are being addressed to ensure completeness of the shareholder registry and compliance with legal and market standards.

Strategic Development: Occupancy of a GMP Production Facility

Another cornerstone of the Company’s operational strategy involves its newly confirmed occupancy of a 20,477 square-foot state-of-the-art pharmaceutical manufacturing and research facility. The Company officially took occupancy on January 12, 2026.

This facility is purpose-built to meet strict current Good Manufacturing Practice (cGMP) standards, and will play a critical role in PurMinds’ clinical and production strategy. GMP certification is a stringent regulatory standard required for pharmaceutical manufacturing and ensures consistency, quality control, and adherence to safety protocols across all production stages.

While PurMinds is in the process of securing fresh regulatory licenses for this site, key infrastructure already in place includes ISO 8 clean rooms, advanced environmental and seismic monitoring systems, and comprehensive security protocols. Previously, the site held both a Controlled Substance License and a Drug Establishment License (DEL), positioning PurMinds to accelerate licensing applications with Health Canada and the U.S. Food and Drug Administration (FDA).

This capability to house in-house GMP production and R&D positions the Company at an operational advantage compared to many peers, giving PurMinds direct control over both early-stage research and scaled pharmaceutical activities.

Regulatory Strategy and OTCQX Uplisting Plan

Beyond manufacturing and research infrastructure, PurMinds has also outlined a broader financial and market transparency strategy — including a planned uplisting from the OTC Pink marketplace to the OTCQX® Best Market. The OTCQX is the highest tier of the OTC Markets Group’s marketplaces, and companies listed here are held to rigorous financial disclosure and corporate governance standards, providing investors access to greater transparency and market confidence.

A critical step toward this uplisting is engaging a PCAOB-registered audit firm. The Public Company Accounting Oversight Board (PCAOB) audit is a requirement for OTCQX eligibility and serves to elevate investor assurance in the Company’s financial reporting. PurMinds expects the audit engagement and associated filings to be completed in the first half of 2026, setting the stage for its OTCQX transition shortly thereafter.

Financial Reporting and Filings

In connection with these corporate developments, PurMinds has published its Annual Report on Form 10-K for the fiscal year ending September 30, 2025. Because the RTO closed on November 3, 2025, the 10-K reflects the pre-merger financial status of Pacific Software and does not consolidate the full PurMinds enterprise operations.

However, the upcoming Quarterly Report on Form 10-Q for the period ending December 31, 2025 — due February 14, 2026 — will be the first consolidated financial filing to reflect the full scope of the RTO, the new capital structure, and the Company’s post-transaction progression. This reporting milestone is anticipated to provide investors, analysts, and stakeholders with fresh insights into the operational and financial basis of PurMinds’ expanded mission.

Executive Commentary on Strategic Progress

Angelo Pizzuto, PurMinds’ Treasury Executive and Chief Operating Officer, commented on the importance of both occupancy of the GMP facility and the ongoing corporate transition. According to Pizzuto, the facility provides a “license-ready” environment that will support the Company’s efforts to obtain essential regulatory certifications crucial for clinical progress and future commercial activities.

He reaffirmed the Company’s commitment to addressing past administrative hurdles, hiring specialized talent, and advancing financial transparency — all elements he described as laying a strong foundation for PurMinds’ leadership in neuromedicine.

About PurMinds Enterprises, Inc.

PurMinds Enterprises, Inc. is a precision neuro-medicine development company committed to advancing treatments and diagnostic capabilities for neurological and psychiatric conditions with high unmet medical need. The Company champions a “4P Medicine” approach — Predictive, Preventive, Personalized, and Participatory — designed to enable early detection and intervention before irreversible neurological damage occurs.

Its clinical pipeline includes novel neuroprotective compounds capable of restoring neuronal function across multiple indications. PurMinds also partners strategically with organizations such as SpectroChip Global Inc. to integrate cutting-edge technological platforms into its research and intervention strategies.

With enhanced GMP production capabilities, a forthcoming OTCQX uplisting, and a mission geared toward meaningful patient impact, PurMinds is strategically positioned to become a recognized leader in the neuro-health marketplace.